EUVIMEDEUVIMED entdecken
Open Access

Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer

Mackenzie A Scully, Dana E Wilkins, Megan N Dang iD, Elise C Hoover iD, Sara B Aboeleneen iD, Emily S Day iD

Molecular Pharmaceutics · 2023

DOI: 10.1021/acs.molpharmaceut.3c00009 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecular Pharmaceutics, 2023. Verfasst von Mackenzie A Scully und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Antineoplastic Agents, Nanoparticles. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, NCI NIH HHS, National Cancer Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Overexpression of the antiapoptotic protein B-cell lymphoma 2 (Bcl-2) is correlated with poor survival outcomes in triple-negative breast cancer (TNBC), making Bcl-2 inhibition a promising strategy to treat this aggressive disease. Unfortunately, Bcl-2 inhibitors developed to date have limited clinical success against solid tumors, owing to poor bioavailability, insufficient tumor delivery, and off-target toxicity. To circumvent these problems, we loaded the Bcl-2 inhibitor ABT-737 in poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) that were wrapped with phospholipid membranes derived from 4T1 murine mammary cancer cells, which mimic the growth and metastasis of human TNBC. We show that the biomimetic cancer cell membrane coating enabled the NPs to preferentially target 4T1 TNBC cells over noncancerous mammary epithelial cells in vitro and significantly increased NP accumulation in orthotopic 4T1 tumors in mice after intravenous injection by over 2-fold compared to poly(ethylene glycol)-poly(lactide-co-glycolic) (PEG-PLGA) copolymer NPs. Congruently, the ABT-737 loaded, cancer cell membrane-wrapped PLGA NPs (ABT CCNPs) induced higher levels of apoptosis in TNBC cells in vitro than ABT-737 delivered freely or in PEG-PLGA NPs. When tested in a syngeneic spontaneous metastasis model, the ABT CCNPs significantly increased apoptosis (evidenced by elevated active caspase-3 and decreased Bcl-2 staining) and decreased proliferation (denoted by reduced Ki67 staining) throughout tumors compared with saline or ABT-loaded PEG-PLGA NP controls. Moreover, the ABT CCNPs did not alter animal weight or blood composition, suggesting that the specificity afforded by the TNBC cell membrane coating mitigated the off-target adverse effects typically associated with ABT-737. Despite these promising results, the low dose of ABT CCNPs administered only modestly reduced primary tumor growth and metastatic nodule formation in the lungs relative to controls. We posit that increasing the dose of ABT CCNPs, altering the treatment schedule, or encapsulating a more potent Bcl-2 inhibitor may yield more robust effects on tumor growth and metastasis. With further development, drug-loaded biomimetic NPs may safely treat solid tumors such as TNBC that are characterized by Bcl-2 overexpression.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsAntineoplastic AgentsNanoparticlesHumansAnimalsMiceCell Line, TumorCell MembranePolyestersPolyethylene GlycolsBiphenyl CompoundsNitrophenolsPiperazinesSulfonamides

Stichwörter der Autor:innen

ABT-737biomimicrymembrane-wrappedmetastasisnanomedicineoncologytargeted chemotherapy

Substanzen

Antineoplastic Agentspolyethylene glycol-poly(lactide-co-glycolide)PolyestersPolyethylene GlycolsABT-737Biphenyl CompoundsNitrophenolsPiperazinesSulfonamidespoly(ethyleneglycol-lactide)

Autor:innen und Institutionen

  • Department of Biomedical Engineering, University of Delaware, Newark, Delaware 19713, United States.
  • Department of Materials Science and Engineering, University of Delaware, Newark, Delaware 19716, United States.
  • Helen F. Graham Cancer Center and Research Institute, Newark, Delaware 19713, United States.

ORCID-Profile: Megan N Dang, Elise C Hoover, Sara B Aboeleneen, Emily S Day

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • National Cancer Institute
  • University of Delaware
  • National Institute of General Medical Sciences
  • Division of Materials Research

Zitieren

APA

Scully, M. A., Wilkins, D. E., Dang, M. N., Hoover, E. C., Aboeleneen, S. B., & Day, E. S. (2023). Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer. Molecular Pharmaceutics. https://doi.org/10.1021/acs.molpharmaceut.3c00009

Vancouver

Scully MA, Wilkins DE, Dang MN, Hoover EC, Aboeleneen SB, Day ES. Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer. Molecular Pharmaceutics. 2023. doi:10.1021/acs.molpharmaceut.3c00009

BibTeX
@article{Scully2023,
  author = {Scully, Mackenzie A and Wilkins, Dana E and Dang, Megan N and Hoover, Elise C and Aboeleneen, Sara B and Day, Emily S},
  title = {Cancer Cell Membrane Wrapped Nanoparticles for the Delivery of a Bcl-2 Inhibitor to Triple-Negative Breast Cancer},
  journal = {Molecular Pharmaceutics},
  year = {2023},
  doi = {10.1021/acs.molpharmaceut.3c00009}
}
Kostenlos starten →